Acadia Pharmaceuticals Inc (ACAD) concluded trading on Thursday at a closing price of $19.77, with 3.15 million shares of worth about $62.23 million changed hands on the day. Half year performance of the stock remained positive as price took a surge of 25.68% during that period and on February 13, 2025 the price saw a gain of about 3.51%. Currently the company’s common shares owned by public are about 166.35M shares, out of which, 164.30M shares are available for trading.
Stock saw a price change of 3.35% in past 5 days and over the past one month there was a price change of 16.98%. Year-to-date (YTD), ACAD shares are showing a performance of 7.74% which decreased to -26.12% when we look at its performance for past 12 months. Over the period of past 52 weeks, stock dropped to lowest price of $14.15 but also hit the highest price of $26.56 during that period. The average intraday trading volume for Acadia Pharmaceuticals Inc shares is 2.42 million. The stock is currently trading 6.38% above its 20-day simple moving average (SMA20), while that difference is up 10.63% for SMA50 and it goes to 19.79% higher than SMA200.
Acadia Pharmaceuticals Inc (NASDAQ: ACAD) currently have 166.35M outstanding shares and institutions hold larger chunk of about 97.13% of that.
The stock has a current market capitalization of $3.29B and its 3Y-monthly beta is at 0.44. PE ratio of stock for trailing 12 months is 25.59, while it has posted earnings per share of $0.77 in the same period. It has Quick Ratio of 2.11 while making debt-to-equity ratio of 0.09. Volatility of a stock is a metric used to know how much the price of that stock is under influence and for ACAD, volatility over the week remained 3.96% while standing at 3.71% over the month.
Stock’s fiscal year EPS is expected to rise by 294.93% while it is estimated to increase by 0.79% in next year.
Digging deeper we find that several firms have released their research notes about the support levels of the stock. Most recent of them is a note released by Deutsche Bank on February 11, 2025 offering a Hold rating for the stock and assigned a target price of $22 to it. Coverage by Guggenheim stated Acadia Pharmaceuticals Inc (ACAD) stock as a Neutral in their note to investors on January 03, 2025, suggesting a price target of $20 for the stock. On October 10, 2024, Raymond James Resumed their recommendations, while on August 07, 2024, Morgan Stanley Downgrade their ratings for the stock with a price target of $20. Stock get an Outperform rating from BMO Capital Markets on June 27, 2024.
